Efficacy and Safety of Omalizumab in Japanese and Korean Patients with Chronic Idopathic/Spontaneous Urticaria (CIU/CSU: Results from the Phase 3 POLARIS Study. J of Skin. 2017;1(3.1):s126. doi:10.25251/skin.1.supp.125